Valerie Oberhardt,Hendrik Luxenburger,Janine Kemming,Isabel Schulien,Kevin Ciminski,Sebastian Giese,Benedikt Csernalabics,Julia Lang-Meli,Iga Janowska,Julian Staniek,Katharina Wild,Kristi Basho,Mircea Stefan Marinescu,Jonas Fuchs,Fernando Topfstedt,Ales Janda,Oezlem Sogukpinar,Hanna Hilger,Katarina Stete,Florian Emmerich,Bertram Bengsch,Cornelius F. Waller,Siegbert Rieg,Sagar,Tobias Boettler,Katharina Zoldan,Georg Kochs,Martin Schwemmle,Marta Rizzi,Robert Thimme,Christoph Neumann-Haefelin,Maike Hofmann

Abstract:Abstract SARS-CoV-2 spike mRNA vaccines 1–3 mediate protection from severe disease as early as ten days after prime vaccination 3 , when neutralizing antibodies are hardly detectable 4–6 . Vaccine-induced CD8 + T cells may therefore be the main mediators of protection at this early stage 7,8 . The details of their induction, comparison to natural infection, and association with other arms of vaccine-induced immunity remain, however, incompletely understood. Here we show on a single-epitope level that a stable and fully functional CD8 + T cell response is vigorously mobilized one week after prime vaccination with bnt162b2, when circulating CD4 + T cells and neutralizing antibodies are still weakly detectable. Boost vaccination induced a robust expansion that generated highly differentiated effector CD8 + T cells; however, neither the functional capacity nor the memory precursor T cell pool was affected. Compared with natural infection, vaccine-induced early memory T cells exhibited similar functional capacities but a different subset distribution. Our results indicate that CD8 + T cells are important effector cells, are expanded in the early protection window after prime vaccination, precede maturation of other effector arms of vaccine-induced immunity and are stably maintained after boost vaccination.

Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine